Another round of good news about the obesity drug Acomplia seems likely to be forthcoming on June 12th when researchers publicly report for the first time on results of the RIO-Diabetes trial at the American Diabetes Association's annual scientific meeting in San Diego.

The year-long Rimonabant in Obesity-Diabetes study, a multi-center trial which enrolled 1,000 obese patients with type 2 diabetes, will be the last of the four major Acomplia studies to report trial results before U.S. and European regulators are expected to act on Sanofi-Aventis' application to bring the drug to market.

In this trial, researchers compared weight-loss, improvements in metabolic variables, and reduction in cardiovascular risk factors for obese diabetics who took Acomplia compared to those on a placebo.

Announcement of the results of the RIO-Diabetes trial is slated for a symposium on "Late-Breaking Clinical Trials" scheduled to be held at 2 pm PDT June 12th.

Researchers have hinted privately to reporters that the results are consistent with the highly encouraging results from their three studies reported earlier -- RIO-North America, RIO-Europe and RIO-Lipids.

The fact that the results are going to be presented at the highest-profile symposium at the American Diabetes Association meeting -- only weeks after Sanofi filed for approval of the drug with the U.S. Food and Drug Administration and European regulators -- also strongly suggests more positive news is forthcoming.

The Acomplia Report will be covering this symposium and related news briefings, and will bring you the latest news on the RIO-Diabetes study as soon as it becomes available.

Other sources: Acomplia Report